Paper - WANFANG MED ONLINE

You Position: Home > Paper

Multi-drug resistant Acinetobacter baumannii-gram-negative "MRSA" in 21st century

( views:616, downloads:589 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES

Issue:: 2

DOI:: 10.3760/cma.j.issn.1674-2397.2009.02.001

Key Word:: 鲍氏不动杆菌;多药耐药;革兰阴性菌;Acinetobacter baumannii;Muhidrug resislance;Gram-negative bacteria

Abstract： @@ 不动杆菌是一类非发酵、严格需氧的革兰阴性杆菌,普遍存在于自然界中.不动杆菌属至少可分为32个基因种型,其中,鲍曼不动杆菌、醋酸钙不动杆菌、不动杆菌基因种型3及13TU通过常规表型鉴定难以区分,合称为鲍曼-醋酸钙不动杆菌复合体.近年来,不动杆菌属在临床样本中的分离率逐年提高,而鲍曼不动杆菌约占其中的80%～90%[1-2].

Reference

[1]汪复,朱德妹,胡付品,等.2007年中国CHINET细菌耐药性监测[J].2008,(5).
[2]Potoski BA,Husain S,Paterson DL,etc.Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.[J].2007,59(1).
[3]G Christopher, Wood,Scott D, Hanes,Martin A, Croce,etc.Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.[J].2002,34(11).
[4]Corbella X,Sora M,Vuelta M,etc.Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii.[J].1998,42(6).
[5]Seifert H,Peleg AY,Paterson DL.Acinetobacter baumannii: emergence of a successful pathogen.[J].2008,21(3).
[6]Louie M,Simor AE,Palmer R,etc.An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management.[J].2002,23(5).
[7]Matthew E, Falagas,Ioannis A, Bliziotis,Ilias I, Siempos.Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies.[J].2006,10(2).
[8]Halstead DC,Abid J,Dowzicky MJ.Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.[J].2007,55(1).
[9]Jeric PE,Quelle LS,Catalano M,etc.Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases.[J].1999,42(1).
[10]Almog Y,Schlaeffer F,Porath A,etc.Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment.[J].2003,54(1).
[11]Bonnal RJ,Cassone A,Bordoni R,etc.Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group.[J].2008,52(7).
[12]Thamlikitkul V,Tiengrim S,Koomanachai P,etc.Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.[J].2007,11(5).
[13]Pujol M,Tubau F,Montero A,etc.Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.[J].2006,58(3).
[14]Jones RN,Sader HS,Gales AC.Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).[J].2006,12(4).
[15]Kelesidis I,Karageorgopoulos DE,Kelesidis T.Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.[J].2008,62(1).
[16]J, Garnacho-Montero,C, Ortiz-Leyba,F J, Jiménez-Jiménez,etc.Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.[J].2003,36(9).
[17]Wareham DW,Gordon NC.A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.[J].2009,63(4).
[18]Mendes RE,Turnidge JD,Bell JM.Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program.[J].2009,63(1).
[19]Michalopoulos A,Hatzopoulou P,Falagas ME,etc.Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.[J].2006,12(12).
[20]Leavitt A,Carmeli Y,Navon-Venezia S.High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.[J].2007,59(4).
[21]Yang Q,Yu YS,Li LJ,etc.Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China.[J].2007,45(12).
[22]Xanthaki A,Betrosian AP,Georgiadis G,etc.High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.[J].2007,39(1).